The recovery time-course of CYP3A after induction by St John's wort administration

British Journal of Clinical Pharmacology

Volumn 65, Issue 5, 2008, Pages 701-707

  Imai, Hiromitsu ^a   Kotegawa, Tsutomu ^a   Tsutsumi, Kimiko ^a   Morimoto, Takuya ^a   Eshima, Nobuoki ^a   Nakano, Shigeyuki ^a   Ohashi, Kyoichi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

CYP3A; Enzyme induction; Recovery time course; St John's wort

Indexed keywords

CYTOCHROME P450 3A; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; MIDAZOLAM; MIDAZOLAM MALEATE; TRUNATURE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; CYTOCHROME P-450 CYP3A; GABA MODULATORS; HUMANS; HYPERICUM; MALE; MIDAZOLAM; PLANT EXTRACTS; TIME FACTORS;

EID: 42149117406     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03120.x     Document Type: Article

References (23)

1. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression: an overview and meta-analysis of randomised clinical trials. BMJ 1996 313 : 253 8.
2. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000 67 : 451 7.
3. Greeson JM, Sanford B, Monti DA. St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 2001 153 : 402 14.
4. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001 70 : 317 26.
5. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003 290 : 1500 4.
6. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ 2004 329 : 27 30.
7. Izzo AA. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharm Ther 2004 42 : 139 48.
8. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003 73 : 41 50.
9. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001 70 : 518 24.
10. Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A. Drug interaction between St John's Wort and quazepam. Br J Clin Pharmacol 2004 58 : 403 10.
11. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 2007 47 : 871 6.
12. He P, Court MH, Greenblatt DJ, von Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 2005 77 : 373 87.
13. Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004 60 : 231 6.
14. Floyd MD, Gervasini G, Masicca AL, Mayo G, George AL Bhat K, Kim RB, Wilkinson GR. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003 13 : 595 606.
15. De los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St John's wort. Am J Health Syst Pharm 2002 59 : 545 7.
16. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004 76 : 330 40.
17. Bornemann LD, Crews T, Chen SS, Twardak S, Patel IH. Influence of food on midazolam absorption. J Clin Pharmacol 1986 26 : 55 9.
18. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996 24 : 796 801.
19. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet 2003 42 : 819 50.
20. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992 41 : 1047 55.
21. Biber A, Fischer HR, ömer A, Chatterjee SS. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiat 1998 31 (Suppl. 36 43.
22. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelly CJ, LeDuc BW, Zinny MA. Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003 74 : 121 9.
23. Takedomi S, Matsuo H, Yamano K, Ohtani H, Sawada Y. In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation. J Pharm Pharmacol 2001 53 : 643 51.